Synopsis: Biocon Limited shares rose 2% as it added three oncology biosimilars, expanding a 17-asset cancer pipeline targeting a $75+ billion opportunity alongside planned Biocon Biologics integration.
The shares of this company, which is in the business of manufacturing biotechnology products like generics, biosimilars, research services and novel biologics, had its shares in the news following the launch of three major oncology biosimilars to strengthen its cancer portfolio.
With the market cap of Rs 52,300 crore, the shares of Biocon Ltd had hit their intraday high at Rs 393.2, gaining about 2 per cent compared to their previous day’s closing price of Rs 385.05. The shares are trading at a PE of 110, whereas their industry PE is at 30.7.
About the launch of 3 oncology biosimilars
The recent announcement by Biocon Biologics regarding expanding their oncology biosimilars is a major strategic move, as they intend to enter the market with proposed biosimilars for major cancer drugs such as Keytruda, Opdivo, and Herceptin SC, which are bestsellers in the market today.
Each of these drugs targets huge market bases, most of which are approaching the expiry of protection, thus offering Biocon Biologics an excellent chance to establish their major foothold in the cancer biosimilar market. With these new additions, Biocon Biologics is going to establish one of the largest cancer biosimilar portfolios in the market.
Alongside the expansion of the pipelines, another structurally significant move announced is the proposed consolidation of Biocon Biologics as a wholly owned subsidiary of Biocon Limited. With this consolidation, it is expected that the structure of the company shall simplify, with optimised resource allocation catering to the vast commercial and manufacturing infrastructural network of Biocon across the globe. Moreover, from a strategic perspective, Biocon stands out in the market because it provides biosimilar insulins and complex peptides, including GLP-1s, as well as oncology biosimilars.
Overall, this twin focus on high-value oncology assets and corporate integration fortifies Biocon’s global competitive positioning. The oncology portfolio itself represents an opportunity of more than US$75 billion, while integration enhances scale and execution capability, and operating leverage across markets. If well executed, such a strategy should, therefore, help further enhance earnings visibility, deepen market penetration, and reinforce Biocon’s long-term ambition of delivering affordable biologic therapies to patients globally.
Financial highlights and more
The revenue from operations for the company stood at Rs 4,296 crores in Q2 FY26 compared to Q2 FY25 revenue of Rs 3,590 crores, up by about 20 per cent YoY. Similarly, the net profit stood at Rs 133 crore in Q2 FY26, up from Rs 27 crore in Q2 FY25.
Biocon Group has a well-diversified life sciences platform in four successfully incubated business areas. Biocon Biologics, accounting for 62% of the total revenue of Biocon Group, leads the business areas by developing biosimilars to make affordable access to biologic therapy possible all over the world. Then, Biocon, accounting for 17% of the total Biocon Group’s revenue, stabilises the business by developing generics & APIs
Next, Syngene, accounting for 21% of the total revenue of Biocon Group’s business areas, begins to generate value by offering end-to-end research & manufacturing solutions to innovators all around the world through CRO & CDMO. However, Bicara Therapeutics stands out despite still being merely pre-revenue & listed on NASDAQ. It represents the innovation horizon of Biocon.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
